Market Size (2018)
$6.53B
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$6.53B
Projected (2025)
$8.48B
CAGR (2016–2025)
4.0%
Key Players
10+
The thoracolumbar junction is present between the thoracic spine and the lumbar spine. Thoracolumbar spine fractures are common injuries that can result in significant disability, deformity, and neurological deficit. Worldwide increasing obese population, high prevalence of spinal cord injuries, and growing geriatric population are some of the major factors driving the market growth. On the contrary, the presence of stringent regulatory policies, lack of awareness for the use of advanced technologies, and fewer product recalls are anticipated to impede the market growth.
Key Contributing Factors
There are numerous factors that contribute to the growth of the thoracolumbar spine devices market. The key factors are mentioned below in brief.
Increasing Obese Population
According to the Organization for Economic Co-operation and Development (OECD), the obese population in the UK was increased from 25.6% of the total population in 2014 to 28.7% of the total population in 2017. In addition, the obese population in the US increased from 38.2% of the total population in 2014 to 40% of the total population in 2016. The rising obese population is likely to support the growth of the global thoracolumbar spine devices market over the forecast period.
High Prevalence of Spinal Cord Injuries (SCI)
As per a study published by the National Spinal Cord Injury Statistical Center in 2019, the annual incidence of spinal cord injury (SCI) is approximately 54 per 1 million individuals in the US or around 17,730 new cases every year. This prevalence of spinal cord injuries is expected to propel the demand for thoracolumbar procedures, thereby assisting in market growth.
Growing Geriatric Population
According to the statistics published by the United Nations (UN), the global population aged 60 years or over was 962 million in 2017, which is projected to double by 2050 (nearly 2.1 billion). The elderly population is more prone to develop the degeneration of spinal discs and cause intervertebral disc disorder (IDD) which is likely to boost the demand for thoracolumbar spine devices over the assessment period.
The Thoracolumbar Spine Devices Market market is projected to grow at a CAGR of 4.0% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThoracolumbar Spine Devices Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
Thoracolumbar junction is the junction between the thoracic spine and the lumbar spine. The junction consists of the part of the vertebral column from the eleventh thoracic vertebra to the first lumbar vertebra. Thoracolumbar spine devices are used in this region to provide steady support to the spine and avoid bending of the thoracic spine. The global thoracolumbar spine devices market has been bifurcated into product type, type of surgery, material, end user, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global thoracolumbar spine devices market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all players competing to gain a stronghold in the market. Worldwide growing obese population, surging prevalence of spinal cord injuries and chronic back pain, increasing inclination of patients and healthcare professionals towards adoption of minimally invasive (MI) techniques, and rising elderly population are some of the factors fueling the market growth. The manufacturers are competing based on cost, quality, and reliability. It is crucial for market participants to provide cost-efficient and high-quality products to sustain and prosper in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Therefore, manufacturers should focus on geographic expansions and product performance improvements. They should chiefly focus on the development of innovative products. Though multinational market players are spearheading the market, regional, and international market players with small market shares also have a noticeable presence. The international market players can expand their presence across the world through mergers and acquisitions made during the assessment period. It has also been predicted that development of the global economic scenario along with efforts to develop healthcare infrastructure in emerging countries is assisting in the market growth, thereby making it an ideal time for new products and to increase the global market share.
B. Braun Melsungen AG (B. Braun) provides its products to hospitals, surgical units, private practices, and extracorporeal blood treatments. The company operates through four major divisions, such as hospital care, Aesculap, outpatient market, and B. Braun Avitum. With these four divisions, it has a wide range of products with about 5,000 products, out of which it manufactures 95% of the products. Geographically it operates in 64 countries in regions such as Europe, Asia-Pacific, Latin America, and the Middle East and Africa. B. Braun is focused on extending its product portfolio and increasing investment in research and development. The company emphasizes expanding geographically through partnerships with its customers to understand their needs and develop appropriate and innovative solutions.
Stryker Corporation (Stryker) is involved in developing, manufacturing, and marketing specialty surgical and medical products. The company's products include implants, biologics, surgical, neurologic, ear, and throat and interventional pain equipment, endoscopic, surgical navigation, communications, and digital imaging systems, along with patient handling and emergency medical equipment. It has classified its products into three major categories, namely, medical and surgical equipment, orthopedics, and neurotechnology. Stryker focuses on new product developments and on enhancing the customer experience and customer engagement. The company is more into acquisitions for developing a huge product line, capture the maximum market share, and to grow in the market successfully. The company focuses on acquisitions to address new sectors, maintaining the innovativeness of its products in all the segments.
Medtronic PLC (Medtronic) is a global healthcare solutions company committed to improving the lives of people through medical technologies, services, and solutions. The company has developed additional core technologies, including implantable mechanical devices, drugs and biologic delivery devices, and powered and advanced energy surgical instruments. These technologies are used to treat nearly 40 medical conditions. The company’s businesses majorly fall into four groups, namely, the Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group, and the Minimally Invasive Therapies Group (MITG). Medtronic develops technologies and solutions in line with its mission to alleviate pain, restore health, and extend life for people. The company focuses on value-based healthcare principles to drive global growth. The company focuses on steady product launches to increase its product line and to improve clinical and economic outcomes across its therapeutic areas. It also focuses on expanding its presence in various regions through mergers and acquisitions.
DePuy Synthes is a part of the Johnson & Johnson family of companies. It offers the most comprehensive portfolio of spine, trauma, sports medicine, neuro, cranio-maxillofacial, power tools, and biomaterials. It is the second-largest spine company in the world. The company's leading solutions include comprehensive systems to treat spinal conditions ranging from scoliosis to degenerative disc disease. The company has a broad portfolio that supports nearly one million orthopedic and neuro procedures worldwide annually.
Zimmer Biomet Holdings, Inc. (Zimmer Biomet) develops, produces, and markets musculoskeletal healthcare products. It is a leading brand in providing customized joint and bone healthcare solutions. It provides products for joint reconstruction, dental reconstruction, sports medicine, and bone and skeletal repair. The company manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities, and trauma products, office-based technologies, spine, craniomaxillofacial and thoracic products, dental implants, and related surgical products. These products and solutions help to treat patients suffering from disorders, injuries, joints, and supporting soft tissues. Zimmer Biomet focuses on expanding the business by meeting the customers’ needs. The company also emphasizes optimizing manufacturing processes to maximize profits. It collaborates with healthcare professionals around the globe to advance the pace of innovation.
Some other participants present in the market are Orthofix Holdings, Inc., Alphatech Holdings, Inc., Exactech, Inc., Globus Medical Inc., and NuVasive Inc.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global thoracolumbar spine devices market is low to moderate. The suppliers in the global thoracolumbar spine devices industry are medical device manufacturers. Currently, a high number of suppliers are present in the market due to high opportunities. Major players are accounting for a significant share of the market. Switching cost of the suppliers is moderate because suppliers tend to enter into long-term associations, partnership, and deals with the companies that sell thoracolumbar spine devices.
Bargaining Power of Buyers
The bargaining power of the buyers is moderate to high in the global thoracolumbar spine devices market due to the presence of many suppliers of thoracolumbar spine devices. The buyers of thoracolumbar spine devices are moderately inclined towards product manufacturers. The market consists of a high number of manufacturers which leads to many options with regards to product offering thus the bargaining power of buyers tends to be moderate to high in this market.
Threat of New Entrants
The threat of new entrants is low to moderate in the global thoracolumbar spine devices market. Any company trying to enter the thoracolumbar spine devices market is required to accept the regulatory standards and product should get approval by regulatory authorities. This market is also characterized by a reasonable degree of brand loyalty, where establishing a brand name is difficult for new entrants. Moreover, products which are already available in the market are patented, and the cost involved in R&D is high, which creates unfavorable conditions for the new entrants in the market.
Threat of Substitutes
The threat of substitutes in the global thoracolumbar spine devices market is low. Substitutes pose a low threat in the global thoracolumbar spine devices market due to the unavailability of similar products which are offered by major market players. The major products used in thoracolumbar spine treatment are implants and instrumentation and spine biologics amongst others. Due to the availability of limited thoracolumbar spine devices, threat of substitutes in the global thoracolumbar spine devices market is low.
Intensity of Rivalry
The degree of competition in the global thoracolumbar spine devices market is high. Many manufacturers are present in the market. The market is shared by many major players, and their market share is fixed, which indicates the intense rivalry. Players are engaged in developing a process to lower their manufacturing cost to overcome the competition. Moreover, the players are also developing advanced techniques to differentiate their product from their rivals.
Market estimates by geography (2025)
InsightNorth America leads with $2.87B by 2025, while Asia Pacific is projected to grow fastest at a 4.7% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $368.70M | $453.90M | $480.60M | 3.0% | 6% |
| North America | $2.02B | $2.53B | $2.87B | 4.0% | 34% |
| Asia Pacific | $1.17B | $1.40B | $1.77B | 4.7% | 21% |
| Europe | $1.94B | $2.42B | $2.72B | 3.8% | 32% |
| South America | $460.50M | $581.20M | $644.20M | 3.8% | 8% |
| Total | $5.96B | $7.38B | $8.48B | 4.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$8.48B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Spinal Implants | $3.52B | 4.0% | 42% |
| Devices and Instrumentation | $2.94B | 4.1% | 35% |
| Spine Biologics | $2.03B | 3.9% | 24% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Thoracolumbar Spine Devices Market covering market dynamics, competitive landscape, and strategic outlook.
The Thoracolumbar Spine Devices Market market is projected to reach $8.48B by 2025, growing at 4.0% CAGR. The Spinal Implants segment holds the largest share.
The human spinal cord, based on anatomy, is divided into three sections, namely, cervical, thoracic, and lumbar. The cervical section is located at the beginning of the skull comprising of first seven vertebrae. The thoracic spine is the midback consisting of the next 12 vertebrae and the section from ribs to sacrum comprises the lumbar section consisting of the five lower vertebrae.
The global thoracolumbar spine devices market is mainly driven by increasing obese population, high prevalence of spinal cord injuries (SCI), and increasing geriatric population. Stringent regulatory policies, lack of awareness for the use of advanced technologies, and product recall may slow down the growth of the market in the future. On the other hand, launch of innovative products is likely to offer lucrative opportunities for the growth of the market.
Obesity is a complex disease which acts as a cause of other illnesses and health problems such as diabetes, heart disease, and blood pressure amongst others. According to a study published by the National Center for Biotechnology Information (NCBI), 2017, obesity adds to the burden of intervertebral disc disorder (IDD) and lower back pain (lumbar section of the spine). As per the Organization for Economic Co-operation and Development (OECD), the obese population in the UK increased from 25.6% of the total population in 2014 to 28.7% of the total population in 2017. Also, the obese population in the US increased from 38.2% of the total population in 2014 to 40% of the total population in 2016. The increase in obese population increases the risk of problems related to the thoracolumbar section which eventually increases the demand for thoracolumbar spine devices. Hence, the rising obese population is expected to increase the growth of the global thoracolumbar spine devices market during the forecast period.
The manufacturers in the global thoracolumbar spine devices market are constantly involved in research and development for the launch of innovative products. For instance, in July 2019, joimax GmbH launched its product line EndoLIF, consisting of three devices, namely, EndoLIF Double Wedge Cage, EndoLIF Delta Cage, and EndoLIF O/On-Cage, used for endoscopic-assisted minimally invasive lumbar interbody fusion. Also, in April 2016, Amendia Inc. launched OmegaLIF expandable lumbar interbody device. The device is an expandable interbody cage designed for the use in the intervertebral body spinal fusion procedures. The launch of new products to meet the increasing need for spinal cord injury treatments provides an excellent opportunity for manufacturers to increase their market share in the global thoracolumbar spine devices market.
Regulatory compliance is the primary hurdle that challenges almost all the industries, including the thoracolumbar spine devices industry. The growing prevalence of spinal cord injuries, as well as increased awareness regarding the benefit of thoracolumbar spine device techniques among healthcare professionals, have contributed to the rapid increase in the demand for thoracolumbar spine devices for the treatment of various spine-related disorders. Although the regulations serve to improve and maintain the quality of devices, the stringency also contributes to curb the growth of the thoracolumbar spine devices market, especially in developing regions such as Asia-Pacific.
The global thoracolumbar spine devices market has witnessed product development in recent years owing to technological advancements. The innovative products include implants and surgery guidance platform. For instance, Stryker received the US Food and Drug Association (FDA) clearance for Tritanium TL, a 3D-printed curved posterior lumbar interbody fusion cage. The other developments were in products used in spine surgeries. For instance, Nuvasive Inc. in April 2018 launched Anterior Lumbar Interbody Fusion (ALIF) Access, the first-ever Maximum Access Surgery (MAS) ALIF retractor platform. Also, robotic guidance platform for surgeries is witnessing demand by surgical centers. Medtronic revealed that since receiving approval from FDA in November 2018, the Mazor X, a third-generation surgical robotic guidance system and eighth-generation navigation system, was used in more than 1,000 procedures in more than 50 hospitals in the US. Apart from implants and devices, the spine biologics segment also provides an opportunity for investment. Notogen Inc., a preclinical biotechnology company, is involved in injectable biological treatment for disc degeneration disease (DDD) and is seeking investment for further research.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 102 companies operating in the Thoracolumbar Spine Devices Market market, including revenue, employee count, and market positioning where available.
Showing 102 of 102 companies
MEDTRONIC PLC
Company Headquarters: Dublin, Ireland Founded: 1949 Workforce: ~91,000 Company Working: Medtronic plc (Medtronic) is a global healthcare solutions company that focuses on improving the lives of people through medical technologies, solutions, and services. The company with Covidien has accelerated and advanced its abilities to create meaningful innovations for hospitals, health systems, and healthcare providers. The company’s businesses majorly fall into four groups: the Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group, and the Minimally Invasive Therapies Group (MITG). Medtronic operates from over 370 locations in almost 160 countries. The company has been at the forefront of the cardiac telemedicine industry with patented technologies such as ambulatory devices with unified analysis & reporting software and on-site diagnostic systems. The company is committed to advancing science in patient monitoring. The company is awarded more than 4,600 patents.
DEPUY SYNTHES
Company Headquarters: Massachusetts, US Founded: 1895 Workforce: 18,000 + Company Working: DePuy Synthes is a subsidiary of Johnson & Johnson Services, Inc. The company is involved in manufacturing and marketing of orthopedic and neurological devices. It operates through business segments including joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools, and biomaterials. Additionally, it is engaged in manufacturing of reconstruction solutions for hip, knee, and shoulder replacement and trauma devices for internal and external fixation, implants, and instruments. It is directly present in more than 60 countries and operates in all major markets.
Novavax, Inc.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Cleveland Biolabs, Inc
Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
SIGA Technologies
Company Headquarters: New York, US Founded: 1995 Workforce: ~50 Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government
Altimmune
Company Headquarters: Maryland, US Founded: 1997 Workforce: ~50 Company Working: Altimmune is a clinical-stage biopharmaceutical business focusing on treating obesity and liver illnesses. The business is working on HepTcell, an immunotherapeutic drug aimed at providing a functional cure for chronic hepatitis B. The company was formed through the merger of PharmAthene, Inc. ("PharmAthene") with the company formerly known as Altimmune
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence